Panacea Biotec Quarterly Results for Trading Insights
In Sept 2025, Panacea Biotec (PANACEABIO) reported revenue ₹150 Cr and net profit ₹-14 Cr — revenue -3.2% YoY. For annual financials, live price and key ratios, visit Panacea Biotec share price chart.
PANACEABIO Quarterly Results — Revenue, Profit & EPS Highlights
Panacea Biotec latest quarter revenue, net profit, EPS and QoQ/YoY growth rates. Also explore PANACEABIO share price history to track price trends across different timeframes.
- Revenue of ₹150 Cr in Sept 2025 (-11.2% vs Mar 2025, -3.2% vs Sept 2024)
- Net Profit of ₹-14 Cr in Sept 2025 (-600.0% vs Mar 2025, -380.0% vs Sept 2024)
- EBITDA of ₹-9 Cr in Sept 2025 (-200.0% vs Mar 2025)
- Operating Margin of -13.0% in Sept 2025 (+7.0pp vs Mar 2025)
- Earnings Per Share of ₹-2.27 in Sept 2025 (-632.3% vs Mar 2025)
Panacea Biotec Quarterly Results — Revenue, EBITDA, Net Profit & EPS
PANACEABIO quarterly revenue, expenses, EBITDA, net profit, EPS and operating margin with QoQ and YoY comparison.
| Metric | Sept 2025 | Mar 2025 | Jun 2025 | Dec 2025 | Sept 2024 | QoQ | YoY |
|---|---|---|---|---|---|---|---|
| Revenue (₹ Cr) | 150 | 169 | 184 | 170 | 155 | -11.2% | -3.2% |
| Net Profit (₹ Cr) | -14 | -2 | 4 | 4 | 5 | - | - |
| EBITDA (₹ Cr) | -9 | 9 | 16 | 17 | 14 | - | - |
| EPS (₹) | -2.27 | -0.31 | 0.66 | 0.65 | 0.77 | - | - |
| Operating Margin (%) | -13.0% | -20.0% | -1.0% | 7.0% | 5.0% | - | - |
PANACEABIO Share Price Trend — 1-Year Movement Across Quarterly Results
Panacea Biotec 1-year share price in ₹ overlaid with quarterly earnings dates — NSE/BSE closing prices. Compare with PANACEABIO stock valuation models to assess whether the stock is under or overvalued.
Revenue Trend (₹ Cr)
Net Profit Trend (₹ Cr)
Operating Margin Trend (%)
PANACEABIO vs Healthcare Peers — Quarterly Revenue, Profit & Market Cap
Panacea Biotec latest quarter revenue and net profit vs Healthcare competitors — market cap, price and earnings comparison.
| Company Latest Quarter | Market Cap (₹ Cr) | Price (₹) | Revenue (₹ Cr) | Net Profit (₹ Cr) | Rev QoQ % | Rev YoY % | Profit Margin % | P/E Ratio |
|---|---|---|---|---|---|---|---|---|
|
Sun Pharmaceutical
Sept 2025 |
₹450,643.09 Cr | 1891.3 | 14,875 | 3,125 | +10.8% | - | 21.0% | 145.5 |
|
Divis Laboratories
Sept 2025 |
₹179,470.03 Cr | 6858.0 | 2,860 | 689 | +7.1% | - | 24.1% | 264.1 |
|
Torrent Pharmaceuti…
Sept 2025 |
₹148,702.77 Cr | 4469.2 | 3,219 | 591 | +11.3% | - | 18.4% | 254.8 |
|
Cipla
Mar 2026 |
₹115,205.68 Cr | 1401.9 | 6,612 | 543 | -14.3% | -4.0% | 8.2% | 204.1 |
|
Dr Reddys Laborator…
Mar 2026 |
₹111,107.68 Cr | 1318.5 | 7,996 | 221 | -12.5% | -11.5% | 2.8% | 497.5 |
All amounts in ₹ Crores